CSL Limited (CMXHF) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Melbourne, VIC, 호주. 현재 CEO는 Gordon Naylor DipCompSc.
CMXHF 을(를) 보유 IPO 날짜 2005-11-18, 32,698 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $46.93B.
CSL Limited is a global biopharmaceutical company founded in 1916 and headquartered in Parkville, Australia. The company researches, develops, manufactures, and distributes biopharmaceutical products across Australia, the United States, Europe, China, and other international markets. Operating through two main divisions—CSL Behring and Seqirus—the company specializes in plasma-derived therapies for immunodeficiency, bleeding disorders, and neurological conditions, as well as non-plasma biotherapeutics and influenza-related products. CSL Behring also generates revenue through licensing and royalties on intellectual property commercialization.
